Personalised Health in Liverpool

 

The University of Liverpool (UoL) is uniquely positioned as a leader in the research and ‘bench-to-bedside’ delivery (clinical translation) of Personalised Health thanks to their partnerships and close association with Liverpool Health Partners and its nine Hospital Trusts.

The new Royal Liverpool University Hospital, due to open in July 2017, promises increased opportunities for the University of Liverpool, particularly with the hospital’s commitment to hosting a dedicated Biochemical Research Centre and a doubling in size of its MHRA-accredited Phase I Clinical Research Unit.

UoLs current work in Personalised Health research and implementation already benefits the region, while demonstrating the way of the future nationally and internationally. 

Strengths in clinical medicine and pharmacology

In Liverpool the core of our personalised approach comes from UoLs pharmacological expertise, with their unique approach to therapeutic risk/benefit analysis and focus on understanding drug toxicity, pharmacogenomics determinants of efficacy and tolerance, and the molecular pharmacology of drug efficacy. 

UoL has one of he UK’s largest pharmacology departments, bringing together more than 40 leading academics and 110 postgraduate students. Read more.

In REF2014, The University’s collaboration with the Liverpool School of Tropical Medicine (LSTM) achieved a strong result in Clinical Medicine with a ranking of 7th in the UK for critical mass of world leading and internationally excellent research. 

First rate facilities and cross cutting research

UoLs biomedical research is supported by state-of-the-art facilities that give them the ability to drive research from patient samples to the laboratory bench and vice versa from newly generated drug compounds into clinical trials.  This supporting infrastructure and facilities are located within one square mile on the Liverpool Biocampus.

  • Genomic research offering the latest high-throughput next generation and 3rd generation sequencing and array platforms, and proteomic research offering more than 17 mass spectrometry platforms;
  • Health informatics and computational biology to manage the increasingly large datasets generated from ‘Omics research;
  • Biostatistics and first rate clinical trials methodology for Phase I-IV trials;
  • Molecular pathology, biomedical imaging and the Liverpool BioInnovation Hub Biobank provide an invaluable resource for research groups investigating the molecular mechanisms involved in a range of medical conditions with the aim of devising new treatments and therapies.

Regional differences

In Liverpool, we serve a population that has a high and complex disease burden: Liverpool residents have the lowest life expectancy in England (~3 years less than the national average and ~7 years less than in SE England).

Liverpool has been referred to as ‘the capital of cancer’ due to cancer rates being 25% higher than the national average.

This means within the region we have a lot of patients at all stages of life (babies, children and adults) that allows us to optimise the continuum from research to clinical delivery.

 
Go Back
 
 
 

Sign up for our newsletter

 

Sign up to receive our free, quarterly e-mail newsletter for news and information from LHP

We won’t use your details for any other purpose, and we won’t pass them on to any other organisation.